Workflow
EXTRAWELL PHAR(00858)
icon
Search documents
精优药业(00858) - 二零二五年三月二十八日举行之股东特别大会投票表决结果
2025-03-28 11:54
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性或完整性亦不 發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 茲 提 述 精 優 藥 業 控 股 有 限 公 司(「 本 公 司 」)日 期 為 二 零 二 五 年 三 月 十 三 日 的 通 函(「 該 通 函」),其中載有股東特別大會(「股東特別大會」)通告(「該通告」)。除文義另有所指外,本 公告所用詞彙與該通函所界定者具有相同涵義。 股東特別大會之投票表決結果 本公司宣佈,該通告所載提呈之決議案(「該決議案」)於二零二五年三月二十八日舉行之股 東特別大會上以投票表決方式獲股東正式通過。 於股東特別大會日期,已發行股份總數為2,390,000,000股,此為賦予股東權利出席股東特別 大會並於會上表決贊成或反對該決議案的股份總數。任何股東在股東特別大會上就該決議 案投票並無受到任何限制。概無任何股份賦予股東權利出席股東特別大會並須放棄就該決 議案投贊成票,及並無任何股東須根據香港聯合交易所有限公司證券上市規則的規定放棄 表 決 權 。 概 無 股 東 於 該 ...
精优药业(00858) - 补充公告,建议委任核数师,股东特别大会通告
2025-03-13 12:55
( 於百慕達註冊成立之有限公司) (股份代號:00858) 補充公告 建議委任核數師 股東特別大會通告 茲提述精優藥業控股有限公司(「本公司」)日期為二零二五年三月十三日有關建議委任核數 師 的 通 函(「 通 函 」)以 及 本 公 司 日 期 為 二 零 二 五 年 三 月 十 三 日 的 股 東 特 別 大 會 通 告(「 通 告」)。除文義另有所指外,本公告所用詞彙與通函所界定者具有相同涵義。本公司擬以下 列資料補充通函及通告。 本公司已於通告附註第(4)項披露﹕「 確定股東出席大會並於會上投票的權利的記錄日期為 二零二五年三月二十八日。本公司將於二零二五年三月二十五日至二零二五年三月二十八 日( 包括首尾兩天 )暫停辦理股東登記,期間將不會辦理股份過戶登記手續。為符合資格出 席大會並於會上投票,所有股份過戶文件連同有關股票最遲必須於二零二五年三月二十四 日下午四時三十分之前送交上述地址之過戶登記分處。 」 董事會謹此宣佈,經進一步考慮後決定取消通告附註第(4)項所述暫停辦理股東登記時段。 因此,概無就出席股東特別大會及於會上投票而設置暫停辦理股東登記時段,而通告附註 第(4)項將以下列內容完全取代: ...
精优药业(00858) - 致非登记股东之通知信函及申请表格 - 有关载有股东特别大会通告之通函及代...
2025-03-12 08:42
(Incorporated in Bermuda with limited liability) (於百慕達註冊成立之有限公司) (Stock Code 股份代號:858) NOTIFICATION LETTER 通知信函 Dear Non-Registered Holder (Note 1) , 13 March 2025 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Circular dated 13 March 2025 and Proxy Form (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at http://www.extrawell.com.hk and the website of The Stoc ...
精优药业(00858) - 致登记股东之通知信函及回条 - 有关载有股东特别大会通告之通函及代表委任...
2025-03-12 08:39
(於百慕達註冊成立之有限公司) (Stock Code 股份代號:858) (Incorporated in Bermuda with limited liability) 13 March 2025 Dear Registered Shareholder(s), NOTIFICATION LETTER 通知信函 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Circular dated 13 March 2025 and Proxy Form (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication are now available on the Company's website at http://www.extrawell.com.hk and the website of The Stock Exchange o ...
精优药业(00858) - 股东特别大会通告
2025-03-12 08:37
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完整性亦不 發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 精優藥業控股有限公司 主席 謝毅 ( 於百慕達註冊成立之有限公司) (股份代號:00858) 股東特別大會通告 茲通告精優藥業控股有限公司(「本公司」)謹訂於二零二五年三月二十八日(星期五 )上午十 一時正假座香港金鐘道95號統一中心十樓統一會議中心一號會議室舉行股東特別大會,藉 以考慮並酌情通過( 無論有否修訂)下列決議案為本公司普通決議案: 普通決議案 「 動 議 委 任 永 拓 富 信 會 計 師 事 務 所 有 限 公 司 為 本 公 司 核 數 師 , 任 期 直 至 本 公 司 下 屆 股 東 週 年大會結束為止,並授權本公司董事會釐定本公司核數師酬金。」 承董事會命 – 2 – 1. 凡有權出席上述大會並於會上投票之本公司股東,均有權以書面方式委派一名或( 倘其持有兩股或以上 本公司股份(「股份」))多名代表代其出席大會,並於會上投票。受委任代表毋須為本公司股東。 2. 倘為股份之聯名持有 ...
精优药业(00858) - 建议委任核数师及股东特别大会通告
2025-03-12 08:35
此 乃 要 件 請 即 處 理 閣 下 如 對 本 通函 之 任 何 內 容 或 應 採 取之 行 動 有 任 何 疑 問 , 應 諮詢 閣 下 之股 票 經 紀 或 其 他 註冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣 下 如 已 售出 或 轉 讓 名 下 所 有 精優 藥 業 控 股 有 限 公 司之 股 份 , 應 立 即 將 本通 函 及 隨 附 之 代 表 委 任 表 格送 交 買 方 或 承 讓 人 或經 手 買 賣 或 轉 讓 之 銀行 、 股 票 經 紀 或 其 他代 理 商 , 以 便 轉 交買方或承讓人。 香 港 交 易 及結 算 所 有 限 公 司 及 香港 聯 合 交 易 所 有 限 公司 對 本 通 函 之 內 容 概不 負 責 , 對 其 準 確 性 或 完 整性 亦 不 發 表 任 何 聲 明, 並 明 確 表 示 概 不 就因 本 通 函 全 部 或 任 何部 分 內 容 而 產 生 或因倚賴該等內容而引致之任何損失承擔任何責任。 除文義另有所指外,本通函內所用詞彙具有本通函「釋義」一節所界定的相同涵義。 本公司謹訂於二零二五年三月二十八日( 星期五 )上午十 ...
精优药业(00858) - 建议委任核数师
2025-03-07 11:45
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完整性亦不 發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 ( 於百慕達註冊成立之有限公司) (股份代號:00858) 建議委任核數師 本公告乃由精優藥業控股有限公司(「本公司」,連同其附屬公司統稱「本集團」)根據香港聯 合交易所有限公司(「聯交所」)證券上市規則第13.51 (4)條作出。 審核委員會在評估委任永拓富信為本公司新核數師時已考慮了多項因素,包括但不限於(i) 永 拓 富 信 的 審 核 建 議 ; (ii) 永 拓 富 信 處 理 聯 交 所 上 市 公 司 審 核 工 作 的 經 驗 、 知 識 及 技 術 能 力;(iii)永拓富信相對於本集團的獨立性及客觀性;(iv)永拓富信的資源與能力;及(v)會計 及財務匯報局所頒佈的指引。基於上文所述,董事會及審核委員會已評估並認為永拓富信 具備獨立性、資格、能力及適合擔任本公司核數師。 – 1 – 股東特別大會 茲提述本公司日期為二零二四年八月十二日之公告有關( 當中包括 )開元信德會計師事務所 有 ...
精优药业(00858) - 致非登记股东之通知信函及申请表格 - 刊发中期报告2024/25之发佈通...
2024-12-17 08:42
(Incorporated in Bermuda with limited liability) (於百慕達註冊成立之有限公司) (Stock Code 股份代號:858) NOTIFICATION LETTER 通知信函 Dear Non-Registered Holder (Note 1) 18 December 2024 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Interim Report 2024/2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at http://www.extrawell.com.hk and the website of The Stock Exchange of Hon ...
精优药业(00858) - 致登记股东之通知信函及回条 - 刊发中期报告2024/25之发佈通知
2024-12-17 08:40
(Incorporated in Bermuda with limited liability) (於百慕達註冊成立之有限公司) (Stock Code 股份代號:858) NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders. 18 December 2024 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Interim Report 2024/2025 (the "Current Corporate Communication") The E ...
精优药业(00858) - 2025 - 中期财报
2024-12-17 08:36
Financial Performance - Revenue for the six months ended September 30, 2024, was HK$30,792,000, compared to HK$30,141,000 for the same period in 2023, representing a growth of 2.2%[9] - Gross profit decreased to HK$11,812,000 from HK$14,891,000, reflecting a decline of 20.8% year-over-year[9] - Profit before income tax for the period was HK$102,376,000, a significant recovery from a loss of HK$235,795,000 in the previous year[9] - Profit attributable to owners of the Company was HK$100,934,000, compared to a loss of HK$237,725,000 in the same period last year[12] - Total comprehensive income for the period was HK$103,910,000, a turnaround from a total comprehensive loss of HK$240,574,000 in the prior year[13] - Basic earnings per share for the period was HK$4.22, compared to a loss per share of HK$9.95 in the previous year[14] - The Group recorded a profit after tax of about HK$101.5 million in the 2024 Interim Period, a turnaround from a loss of about HK$236.9 million in the 2023 Interim Period[120] - The profit turnaround was mainly due to a non-cash gain of about HK$111.2 million from the fair value change of financial assets, compared to a loss of about HK$225.9 million in the previous period[120] Assets and Liabilities - Total assets increased to HK$1,399,449,000 as of September 30, 2024, compared to HK$1,287,189,000 as of March 31, 2024, representing a growth of approximately 8.7%[4] - Current assets rose to HK$934,770,000, up from HK$177,442,000, indicating a significant increase of approximately 426.5%[4] - Total equity attributable to owners of the Company reached HK$1,216,476,000, an increase from HK$1,113,125,000, reflecting a growth of about 9.3%[7] - Non-current liabilities, including convertible bonds, increased to HK$127,642,000 from HK$117,124,000, marking an increase of approximately 13.0%[7] - Total liabilities decreased to HK$1,399,449,000 from HK$1,287,189,000, indicating a reduction of approximately 8.7%[7] - Cash and bank balances stood at HK$94,107,000, slightly up from HK$93,610,000, indicating a marginal increase of about 0.5%[4] - The outstanding principal amount of the Company's 20-year zero coupon convertible bonds was HK$577.17 million as of September 30, 2024, unchanged from March 31, 2024[139] Investments and Fair Value - Investments in convertible bonds amounted to HK$660,564,000 as of 30 September 2024[29] - The fair value of the Innovative Pharm Bonds at 30 September 2023 is HK$567,611,000, reflecting a change of (HK$290,826,000) in fair value recognized in profit or loss[38] - The fair value at 30 September 2024 is HK$771,793,000, with an unrealized change of HK$111,229,000 since 31 March 2024[40] - The fair value change of the Innovative Pharm Bonds recorded an unrealized gain of about HK$111.2 million in the 2024 Interim Period, compared to an unrealized loss of about HK$225.9 million in the 2023 Interim Period[129] - The fair value hierarchy of unlisted investment funds and unlisted shares is classified as Level 2, with their fair values remaining zero due to net liabilities[110] - The fair value of short-term investments, such as bank structured products, is also classified as Level 2, determined by estimated returns and credit quality[110] - Investments in convertible bonds are classified as Level 3, with fair value determined through management discussions and independent valuation, considering factors like risk-free rates and expected volatility[112] Cash Flow and Operating Activities - Net cash generated from operating activities was HK$119,000, a recovery from cash used of HK$6,380,000 in the same period last year[21] - Cash and cash equivalents at the end of the period increased to HK$94,107,000 from HK$89,786,000 year-over-year[21] - Other income for the period was HK$3,032,000, slightly down from HK$3,137,000 in the previous year[9] Expenses and Costs - The cost of inventories recognized as expenses was HK$6,790,000, an increase from HK$5,938,000 in the same period last year, representing a rise of approximately 14.4%[83] - Staff costs, including directors' emoluments, totaled HK$9,809,000 for the six months ended September 30, 2024, compared to HK$8,977,000 in 2023, marking an increase of about 9.2%[83] - Selling and distribution expenses decreased by about HK$2.3 million or 34.6%, from approximately HK$6.7 million in the 2023 Interim Period to about HK$4.4 million in the 2024 Interim Period[131] - Administrative expenses decreased by about HK$1.1 million or 9.2%, from approximately HK$11.5 million in the 2023 Interim Period to about HK$10.4 million in the 2024 Interim Period[132] Market and Economic Environment - The Group's operating environment in the pharmaceutical manufacturing sector is increasingly challenging due to structural transformations and regulatory changes in China's medical and health system[120] - China's economy recorded a growth of 4.8% year-on-year in the first three quarters of 2024, supported by strong policies and reforms[118] - The Chinese pharmaceutical market continues to witness stable growth, presenting both opportunities and challenges for the Group[124] Corporate Governance and Compliance - The audit committee has reviewed the unaudited condensed consolidated interim financial information and confirmed compliance with current accounting practices in Hong Kong[177] - The remuneration committee oversees the remuneration policies of the group, ensuring alignment with industry standards[178] - The nomination committee is responsible for formulating and implementing policies for nominating candidates for election by shareholders[179] - The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers, ensuring compliance by its directors throughout the 2024 Interim Period[158] Share Capital and Dividends - The Company has not established a dividend policy, preferring to determine dividend payments based on financial performance and market conditions[156] - The company did not recommend the payment of an interim dividend for the six months ended 30 September 2024, consistent with no dividend declared for the same period in 2023[91] - As of September 30, 2024, the Company had a total of 2,390,000,000 shares issued, with potential conversion rights indicating that UG International could hold approximately 27.36% of the enlarged share capital[164] Employment and Staff - As of 30 September 2024, the Group employed 162 staff, a decrease from 169 employees as of 30 September 2023[150] - Staff costs for the 2024 Interim Period amounted to approximately HK$10.9 million, up from HK$10.2 million in the 2023 Interim Period, primarily due to increased performance-related rewards[150]